Stansberry Research

U.S. Late-Day Stock Moves: MRNA, CTAS, MAXR, FGEN, AOUT

Daniel SmootStansberry NewsWire


  • Moderna (MRNA) +9.5%. MRNA will join the S&P 500.
  • Cintas (CTAS) +4.8%. CTAS shares were upgraded from "neutral" to "outperform" at Baird.
  • Maxar Technologies (MAXR) +2%. MAXR shares were initiated as "overweight" at Morgan Stanley.


  • FibroGen (FGEN) -45.9%. The U.S. Food and Drug Administration voted against the company's treatment for anemia in chronic kidney disease treatments.
  • American Outdoor Brands (AOUT) -21.5%. AOUT's fourth-quarter revenue disappointed.